Ciclopirox Suspension
Loading...Ciclopirox Suspension Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Ciclopirox Topical Suspension USP is not for ophthalmic use.
Keep out of reach of children.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Ciclopirox Topical Suspension USP is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur.
History
There is currently no drug history available for this drug.
Other Information
Ciclopirox Topical Suspension USP, 0.77% is for topical use.
Each gram of Ciclopirox Topical Suspension USP contains 7.70 mg of ciclopirox (as ciclopirox olamine) in a water miscible suspension base consisting of cetyl alcohol, cocamide DEA, lactic acid, mineral oil, myristyl alcohol, octyldodecanol, polysorbate 60, purified water, sorbitan monostearate, stearyl alcohol, and benzyl alcohol (1%) as preservative.
Ciclopirox Topical Suspension USP contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt.
The CAS Registry Number is 41621-49-2.
The chemical structure is:
Ciclopirox Topical Suspension USP has a pH of 7.
Sources
Ciclopirox Suspension Manufacturers
-
Taro Pharmaceuticals U.s.a., Inc.
![Ciclopirox Suspension [Taro Pharmaceuticals U.s.a., Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Ciclopirox Suspension | Taro Pharmaceuticals U.s.a., Inc.
Gently massage Ciclopirox Topical Suspension USP, 0.77% into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Topical Suspension USP, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.
Login To Your Free Account